Prothena (0PT) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0PT Analyst Ratings

Moderate Buy

3 Buy

1 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Prothena

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0PT Stock 12 Month Forecast

Average Price Target

€17.66

▲(123.60% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is €17.66 with a high forecast of €30.57 and a low forecast of €6.79. The average price target represents a 123.60% change from the last price of €7.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","31":"€31","9.25":"€9.25","16.5":"€16.5","23.75":"€23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.57298884,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.664393552,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.79399752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.7,10.382537603076923,12.065075206153846,13.74761280923077,15.430150412307693,17.112688015384613,18.795225618461536,20.47776322153846,22.160300824615383,23.842838427692307,25.52537603076923,27.207913633846154,28.890451236923077,{"y":30.57298884,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.7,9.389568734769231,10.07913746953846,10.768706204307692,11.458274939076922,12.147843673846154,12.837412408615386,13.526981143384615,14.216549878153845,14.906118612923077,15.595687347692309,16.285256082461537,16.97482481723077,{"y":17.664393552,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.7,8.553384424615384,8.406768849230769,8.260153273846154,8.113537698461538,7.966922123076922,7.820306547692307,7.673690972307692,7.527075396923077,7.3804598215384605,7.233844246153845,7.08722867076923,6.940613095384615,{"y":6.79399752,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€30.57

Average Price Target€17.66

Lowest Price Target€6.79

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

€25.6

Buy

224.06%

Upside

Reiterated

12/03/25

H.C. Wainwright Remains a Buy on Prothena (PRTA)

Jason Butler

Citizens JMP

€9.39→€16.21

Buy

105.24%

Upside

Reiterated

12/01/25

Prothena price target raised to $19 from $11 at Citizens JMPProthena price target raised to $19 from $11 at Citizens JMP

Tazeen Ahmad

Bank of America Securities

€3.41→€6.83

Sell

-13.58%

Downside

Reiterated

11/21/25

Sell Rating for Prothena Due to Reliance on Partnered Programs and Uncertainties in Phase 3 Trials

Yasmeen Rahimi

Piper Sandler

€30.72

Buy

288.87%

Upside

Reiterated

11/20/25

Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)

Brian Abrahams

RBC Capital

€9.39

Hold

18.82%

Upside

Reiterated

11/06/25

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

Rudy Li

Chardan Capital

€15.36

Buy

94.43%

Upside

Reiterated

08/28/25

Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Eric Schmidt FCA

Cantor Fitzgerald

―

Hold

―

Reiterated

06/20/25

Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)

Jay Olson

Oppenheimer

―

Hold

―

Reiterated

06/16/25

Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)

Michael Yee

Jefferies

€27.31→€5.12

Hold

-35.19%

Downside

Downgraded

05/27/25

Prothena's Hold Rating: Clinical Trial Challenges and Financial PressuresJefferies analyst Michael Yee downgraded Prothena Corp (NASDAQ: PRTA) from Buy to Hold with a price target of $6.00 (from $32.00).

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

02/21/25

Analysts Are Bullish on Top Healthcare Stocks: Prothena (PRTA), Dexcom (DXCM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

€25.6

Buy

224.06%

Upside

Reiterated

12/03/25

H.C. Wainwright Remains a Buy on Prothena (PRTA)

Jason Butler

Citizens JMP

€9.39→€16.21

Buy

105.24%

Upside

Reiterated

12/01/25

Prothena price target raised to $19 from $11 at Citizens JMPProthena price target raised to $19 from $11 at Citizens JMP

Tazeen Ahmad

Bank of America Securities

€3.41→€6.83

Sell

-13.58%

Downside

Reiterated

11/21/25

Sell Rating for Prothena Due to Reliance on Partnered Programs and Uncertainties in Phase 3 Trials

Yasmeen Rahimi

Piper Sandler

€30.72

Buy

288.87%

Upside

Reiterated

11/20/25

Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)

Brian Abrahams

RBC Capital

€9.39

Hold

18.82%

Upside

Reiterated

11/06/25

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

Rudy Li

Chardan Capital

€15.36

Buy

94.43%

Upside

Reiterated

08/28/25

Analysts Offer Insights on Healthcare Companies: Prothena (NASDAQ: PRTA) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Eric Schmidt FCA

Cantor Fitzgerald

―

Hold

―

Reiterated

06/20/25

Cantor Fitzgerald Keeps Their Hold Rating on Prothena (PRTA)

Jay Olson

Oppenheimer

―

Hold

―

Reiterated

06/16/25

Oppenheimer Sticks to Their Hold Rating for Prothena (PRTA)

Michael Yee

Jefferies

€27.31→€5.12

Hold

-35.19%

Downside

Downgraded

05/27/25

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

02/21/25

Analysts Are Bullish on Top Healthcare Stocks: Prothena (PRTA), Dexcom (DXCM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Prothena

1 Month

xxx

Success Rate

7/23 ratings generated profit

Average Return

-2.90%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 30.43% of your transactions generating a profit, with an average return of -2.90% per trade.

3 Months

xxx

Success Rate

8/23 ratings generated profit

Average Return

-4.98%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 34.78% of your transactions generating a profit, with an average return of -4.98% per trade.

1 Year

Jason ButlerCitizens JMP

Success Rate

5/23 ratings generated profit

Average Return

-24.04%

reiterated a buy rating 24 days ago

Copying Jason Butler's trades and holding each position for 1 Year would result in 21.74% of your transactions generating a profit, with an average return of -24.04% per trade.

2 Years

xxx

Success Rate

2/15 ratings generated profit

Average Return

-36.75%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -36.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0PT Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0PT has received 10 Buy Ratings, 4 Hold Ratings, and 1 Sell Ratings. 0PT average Analyst price target in the past 3 months is 17.66.

Each month's total comprises the sum of three months' worth of ratings.

0PT Financial Forecast

0PT Earnings Forecast

Next quarter’s earnings estimate for 0PT is -€0.50 with a range of -€0.78 to -€0.33. The previous quarter’s EPS was -€0.58. 0PT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 0PT has Performed in-line its overall industry.

0PT Sales Forecast

Next quarter’s sales forecast for 0PT is €1.19M with a range of €0.00 to €4.56M. The previous quarter’s sales results were €2.06M. 0PT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 0PT has Performed in-line its overall industry.

0PT Stock Forecast FAQ

What is DE:0PT’s average 12-month price target, according to analysts?

Based on analyst ratings, Prothena’s 12-month average price target is 17.66.

What is DE:0PT’s upside potential, based on the analysts’ average price target?

Prothena has 123.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Prothena a Buy, Sell or Hold?

Prothena has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 1 hold ratings and 1 sell ratings.

What is Prothena’s share price target?

The average share price target for Prothena is 17.66. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €30.57 ,and the lowest forecast is €6.79. The average share price target represents 123.60% Increase from the current price of €7.9.

What do analysts say about Prothena?

Prothena’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Prothena?

To buy shares of DE:0PT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Prothena (0PT) Stock Forecast & Price Target

0PT Analyst Ratings

0PT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Prothena

0PT Analyst Recommendation Trends

0PT Financial Forecast

0PT Earnings Forecast

0PT Sales Forecast

0PT Stock Forecast FAQ

Detailed List of Analyst Forecasts